GPhA After Jaeger: Will Industry Pressures Push Firms Together Or Pull Association Apart? New CEO Must Face Down FOBs
Executive Summary
The Generic Pharmaceutical Association's search for a new president will likely include some soul searching by the association as well
You may also be interested in...
BIO Stalwart Greenwood Announces Departure
Long-time CEO of the Biotechnology Innovation Organization will remain until after the 2020 election and help with the leadership transition.
GPhA’s Next CEO Will Face Political, Regulatory Headwinds
Ralph Neas will leave the generics association in the fall after a successor is found, as user fee and exclusivity reforms await.
GPhA’s Neas Preaches Vigilance Against Reopening Hatch-Waxman Act
After five months on the job, Generic Pharmaceutical Association President and CEO Ralph Neas is optimistic about the industry’s future but prepared to do battle against any efforts to re-work the landmark 1984 law. Preparations include establishing a new non-profit arm, the Affordable Medicine Research Institute, which will focus on research and public education about generics and biosimilars.